PubRank

Arul M Chinnaiyan

Author PubWeight™ 658.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005 39.06
2 The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002 18.30
3 ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004 17.08
4 Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 2003 14.79
5 EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003 13.68
6 ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics 2009 13.34
7 Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009 12.58
8 The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012 11.82
9 Transcriptome sequencing to detect gene fusions in cancer. Nature 2009 11.63
10 Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007 10.94
11 Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007 10.74
12 TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008 9.88
13 Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004 9.42
14 Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2006 8.49
15 TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006 7.61
16 Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008 7.59
17 Autoantibody signatures in prostate cancer. N Engl J Med 2005 7.56
18 Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002 7.29
19 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009 7.09
20 An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010 6.76
21 Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011 6.54
22 The emergence of lncRNAs in cancer biology. Cancer Discov 2011 6.32
23 TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007 6.09
24 Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008 6.08
25 Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005 6.04
26 A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007 5.99
27 Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008 5.92
28 Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004 5.88
29 Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011 5.82
30 DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015 5.39
31 Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 2009 5.30
32 EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008 5.22
33 alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002 5.07
34 TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006 4.99
35 Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010 4.81
36 Integrative analysis of the cancer transcriptome. Nat Genet 2005 4.44
37 Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007 4.43
38 Expressed pseudogenes in the transcriptional landscape of human cancers. Cell 2012 4.22
39 Probabilistic model of the human protein-protein interaction network. Nat Biotechnol 2005 3.99
40 Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013 3.96
41 A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007 3.82
42 Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003 3.73
43 Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010 3.66
44 Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008 3.59
45 Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008 3.55
46 Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011 3.53
47 Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011 3.43
48 The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 2013 3.39
49 Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007 3.37
50 A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008 3.35
51 Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009 3.31
52 Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013 3.13
53 Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 2007 3.06
54 Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008 3.02
55 ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009 2.91
56 Common gene rearrangements in prostate cancer. J Clin Oncol 2011 2.89
57 Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005 2.88
58 A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008 2.87
59 The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008 2.87
60 Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011 2.83
61 Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 2011 2.77
62 ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011 2.74
63 Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009 2.69
64 Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003 2.62
65 Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011 2.62
66 Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007 2.60
67 JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004 2.59
68 New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res 2009 2.56
69 Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 2005 2.55
70 Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009 2.51
71 Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2010 2.50
72 Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol 2002 2.50
73 Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006 2.46
74 HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data. BMC Bioinformatics 2010 2.41
75 Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006 2.39
76 Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005 2.31
77 Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 2013 2.30
78 Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 2011 2.21
79 Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007 2.14
80 Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002 2.10
81 FIZZ1 stimulation of myofibroblast differentiation. Am J Pathol 2004 2.06
82 Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. BMC Genomics 2004 2.02
83 Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov 2011 2.02
84 A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005 2.02
85 Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012 2.00
86 Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004 1.99
87 Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med 2006 1.95
88 Feature selection and molecular classification of cancer using genetic programming. Neoplasia 2007 1.94
89 Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum 2006 1.92
90 Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 2007 1.91
91 Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 2006 1.88
92 Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 2011 1.86
93 Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat Rev Genet 2010 1.82
94 Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004 1.82
95 Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004 1.82
96 Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004 1.80
97 Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 2006 1.78
98 Statistical issues and methods for meta-analysis of microarray data: a case study in prostate cancer. Funct Integr Genomics 2003 1.77
99 Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007 1.75
100 Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 2004 1.74
101 Mixture modelling of gene expression data from microarray experiments. Bioinformatics 2002 1.73
102 Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Ann N Y Acad Sci 2004 1.73
103 Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood 2011 1.67
104 On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Res 2010 1.67
105 Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012 1.63
106 Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011 1.63
107 Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009 1.61
108 PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 2012 1.61
109 Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol 2003 1.60
110 Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 2006 1.54
111 The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 2002 1.52
112 Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J 2004 1.51
113 Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev 2009 1.51
114 Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol 2008 1.48
115 A latent variable approach for meta-analysis of gene expression data from multiple microarray experiments. BMC Bioinformatics 2007 1.48
116 Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003 1.47
117 An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol 2009 1.47
118 The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 2007 1.46
119 Integrative biology of prostate cancer progression. Annu Rev Pathol 2006 1.45
120 The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004 1.45
121 A comparison of single molecule and amplification based sequencing of cancer transcriptomes. PLoS One 2011 1.44
122 AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A 2009 1.43
123 From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012 1.42
124 The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia 2005 1.42
125 Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia 2006 1.41
126 PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 2014 1.39
127 Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006 1.39
128 Exploring clinical associations using '-omics' based enrichment analyses. PLoS One 2009 1.38
129 CXCL5 promotes prostate cancer progression. Neoplasia 2008 1.37
130 KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008 1.36
131 Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012 1.36
132 Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2011 1.36
133 Metabolism unhinged: IDH mutations in cancer. Nat Med 2011 1.35
134 Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation. Biostatistics 2008 1.35
135 C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 2004 1.34
136 alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002 1.34
137 Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 2012 1.34
138 Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005 1.33
139 From bytes to bedside: data integration and computational biology for translational cancer research. PLoS Comput Biol 2007 1.27
140 Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007 1.26
141 Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009 1.23
142 Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 2013 1.23
143 Classification and selection of biomarkers in genomic data using LASSO. J Biomed Biotechnol 2005 1.23
144 Bioinformatics approaches in the study of cancer. Curr Mol Med 2007 1.23
145 Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res 2009 1.20
146 Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 2014 1.19
147 The role of sarcosine metabolism in prostate cancer progression. Neoplasia 2013 1.18
148 The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 2003 1.18
149 The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med 2014 1.17
150 Translating genomics for precision cancer medicine. Annu Rev Genomics Hum Genet 2014 1.17
151 The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev 2011 1.17
152 Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011 1.16
153 Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013 1.16
154 Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 2004 1.15
155 The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget 2014 1.14
156 Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS One 2009 1.14
157 ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010 1.14
158 Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov 2013 1.13
159 Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 2009 1.13
160 A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. Neoplasia 2008 1.12
161 Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate 2014 1.10
162 ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 2006 1.10
163 "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. PLoS One 2010 1.10
164 Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008 1.09
165 Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Brief Funct Genomic Proteomic 2009 1.09
166 Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics 2007 1.09
167 Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 2001 1.09
168 CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. J Cell Biochem 2008 1.08
169 Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia 2012 1.08
170 Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol 2012 1.07
171 Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Res 2006 1.07
172 Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. Int J Biochem Cell Biol 2012 1.07
173 RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia 2009 1.06
174 Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med 2012 1.06
175 The registry case finding engine: an automated tool to identify cancer cases from unstructured, free-text pathology reports and clinical notes. J Am Coll Surg 2007 1.05
176 Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol 2012 1.05
177 Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009 1.05
178 A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002 1.05
179 Translocations in epithelial cancers. Biochim Biophys Acta 2009 1.04
180 Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol 2014 1.04
181 Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. Genome Biol 2015 1.03
182 HIV infection reveals widespread expansion of novel centromeric human endogenous retroviruses. Genome Res 2013 1.03
183 Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. J Proteome Res 2011 1.02
184 Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia 2012 1.01
185 Pathway analysis reveals functional convergence of gene expression profiles in breast cancer. BMC Med Genomics 2008 1.00
186 Molecular markers of prostate cancer. Urol Oncol 2006 1.00
187 Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 2006 1.00
188 The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. J Biol Chem 2005 0.99
189 Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2013 0.99
190 TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res 2011 0.99
191 Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. J Clin Invest 2013 0.98
192 Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003 0.97
193 Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol 2013 0.97
194 The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anat Pathol 2009 0.95
195 SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing. Cancer Discov 2012 0.95
196 Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 2005 0.95
197 Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther 2012 0.95
198 Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol Med 2006 0.95
199 The bright side of dark matter: lncRNAs in cancer. J Clin Invest 2016 0.94
200 A dual role for receptor-interacting protein kinase 2 (RIP2) kinase activity in nucleotide-binding oligomerization domain 2 (NOD2)-dependent autophagy. J Biol Chem 2012 0.94
201 RNA-Seq unleashed. Nat Biotechnol 2011 0.94
202 AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. J Thorac Oncol 2008 0.94
203 Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol 2014 0.93
204 Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res 2009 0.93
205 ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 2010 0.93
206 Oculus: faster sequence alignment by streaming read compression. BMC Bioinformatics 2012 0.93
207 Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis 2012 0.92
208 Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys 2008 0.92
209 HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol 2014 0.92
210 Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res 2013 0.92
211 Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. Cancer Res 2006 0.92
212 The discovery and application of gene fusions in prostate cancer. BJU Int 2008 0.91
213 Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proc Natl Acad Sci U S A 2012 0.91
214 Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest 2006 0.90
215 Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat Commun 2013 0.90
216 Internet-based Profiler system as integrative framework to support translational research. BMC Bioinformatics 2005 0.90
217 Integrating biomedical knowledge to model pathways of prostate cancer progression. Cell Cycle 2007 0.90
218 Protein microarrays using liquid phase fractionation of cell lysates. Proteomics 2003 0.90
219 MicroRNA expression patterns in indeterminate inflammatory bowel disease. Mod Pathol 2012 0.90
220 Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res 2010 0.90
221 Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int J Cancer 2006 0.89
222 The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells. Gastroenterology 2012 0.88
223 Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004 0.88
224 The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease. Blood 2013 0.88
225 Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia 2013 0.88
226 An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status. Trans Am Clin Climatol Assoc 2008 0.86
227 Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J Clin Invest 2015 0.86
228 HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. J Proteome Res 2013 0.86
229 Next-generation sequencing identifies the Danforth's short tail mouse mutation as a retrotransposon insertion affecting Ptf1a expression. PLoS Genet 2013 0.86
230 Covariate adjustment in the analysis of microarray data from clinical studies. Funct Integr Genomics 2004 0.85
231 Of mice and men: cancer gene discovery using comparative oncogenomics. Cancer Cell 2006 0.84
232 High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res 2002 0.84
233 Development of an internally controlled antibody microarray. Mol Cell Proteomics 2005 0.83
234 Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer. Proteomics 2010 0.83
235 Active surveillance for prostate cancer: the role of the pathologist. Pathology 2015 0.82
236 Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Cancer Epidemiol Biomarkers Prev 2005 0.82
237 Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol 2003 0.82
238 A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium. J Urol 2008 0.81
239 miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers. BMC Genomics 2013 0.81
240 Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur Urol 2010 0.81
241 A systems approach to model metastatic progression. Cancer Res 2006 0.81
242 Prostate cancer biomarkers: a current perspective. Expert Rev Mol Diagn 2003 0.80
243 Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. Cancer Immunol Immunother 2008 0.80
244 MetaboID: a graphical user interface package for assignment of 1H NMR spectra of bodyfluids and tissues. J Magn Reson 2012 0.79
245 Insights into Chinese prostate cancer with RNA-seq. Cell Res 2012 0.78
246 Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data. Genomics 2012 0.78
247 AGTR1 as a therapeutic target in ER-positive and ERBB2-negative breast cancer cases. Cell Cycle 2009 0.78
248 The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. J Biol Chem 2012 0.77
249 Disruptive events in the life of prostate cancer. Cancer Cell 2011 0.77
250 Variable reference alignment: an improved peak alignment protocol for NMR spectral data with large intersample variation. Anal Chem 2012 0.77
251 DNA microarrays: implications for clinical medicine. J Invest Surg 2002 0.77
252 Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. Transl Oncol 2013 0.77
253 Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet 2016 0.77
254 Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am J Clin Pathol 2013 0.76
255 PubMed QUEST: the PubMed query search tool. an informatics tool to aid cancer centers and cancer investigators in searching the PubMed databases. Cancer Inform 2007 0.75
256 Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. Am J Surg Pathol 2015 0.75
257 Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. J Innate Immun 2016 0.75
258 Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes. Am J Surg Pathol 2017 0.75
259 A FIRE-y PAGE in the computational analysis of cancer profiles. Mol Cell 2009 0.75
260 Applications of genetic programming in cancer research. Int J Biochem Cell Biol 2008 0.75
261 Gene Fusion Markup Language: a prototype for exchanging gene fusion data. BMC Bioinformatics 2012 0.75
262 Protein microarrays: a powerful tool to study cancer. Curr Opin Mol Ther 2002 0.75
263 A SLAMS dunk for cancer regulators. Nat Biotechnol 2006 0.75
264 Comprehensive Immunophenotypic Characterization of Adult and Fetal Testes, the Excretory Duct System, and Testicular and Epididymal Appendages. Appl Immunohistochem Mol Morphol 2016 0.75
265 Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 2017 0.75
266 Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3. Am J Surg Pathol 2014 0.75
267 Identifying significant associations using free text problem summary lists in a clinical data repository. AMIA Annu Symp Proc 2007 0.75
268 Integrative Clinical Genomics of Advanced Prostate Cancer. Cell 2015 0.75
269 Corrigendum: TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun 2016 0.75
270 Using protein microarrays to study cancer. Biotechniques 2002 0.75
271 Empirical Bayes identification [correction of identication] of tumor progression genes from microarray data. Biom J 2007 0.75
272 Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study. Appl Immunohistochem Mol Morphol 2017 0.75